WO2021207517A3 - Modified hr2 peptide inhibitors of coronavirus fusion - Google Patents

Modified hr2 peptide inhibitors of coronavirus fusion Download PDF

Info

Publication number
WO2021207517A3
WO2021207517A3 PCT/US2021/026416 US2021026416W WO2021207517A3 WO 2021207517 A3 WO2021207517 A3 WO 2021207517A3 US 2021026416 W US2021026416 W US 2021026416W WO 2021207517 A3 WO2021207517 A3 WO 2021207517A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
fusion
peptide inhibitors
peptides
coronavirus
Prior art date
Application number
PCT/US2021/026416
Other languages
French (fr)
Other versions
WO2021207517A2 (en
Inventor
Gene Merutka
Original Assignee
Sapience Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics, Inc. filed Critical Sapience Therapeutics, Inc.
Publication of WO2021207517A2 publication Critical patent/WO2021207517A2/en
Publication of WO2021207517A3 publication Critical patent/WO2021207517A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are modified HR2 peptides that are capable of competing with the native HR2 region of a viral spike (S) protein for binding to the HR1 region, thereby inhibiting formation of the 6-HB fusion complex and fusion with a target host cell, compositions comprising the modified HR2 peptides, and methods of inhibiting viral fusion using the HR2 peptides.
PCT/US2021/026416 2020-04-10 2021-04-08 Modified hr2 peptide inhibitors of coronavirus fusion WO2021207517A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063008469P 2020-04-10 2020-04-10
US63/008,469 2020-04-10

Publications (2)

Publication Number Publication Date
WO2021207517A2 WO2021207517A2 (en) 2021-10-14
WO2021207517A3 true WO2021207517A3 (en) 2022-01-06

Family

ID=78023205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/026416 WO2021207517A2 (en) 2020-04-10 2021-04-08 Modified hr2 peptide inhibitors of coronavirus fusion

Country Status (1)

Country Link
WO (1) WO2021207517A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
WO2023159113A1 (en) * 2022-02-16 2023-08-24 Greene Warner C Peptide fusion inhibitors exhibiting pan-coronavirus inhibitory activity
CN115746148B (en) * 2022-10-14 2023-09-12 中国医学科学院病原生物学研究所 Proteins with coronavirus RBD and membrane fusion inhibiting polypeptides and their use as coronavirus inhibitors
WO2024213127A1 (en) * 2023-04-12 2024-10-17 Westlake University Fusion lipopeptide for inhibiting coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053728A2 (en) * 2000-12-29 2002-07-11 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20160237123A1 (en) * 2008-01-23 2016-08-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053728A2 (en) * 2000-12-29 2002-07-11 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20160237123A1 (en) * 2008-01-23 2016-08-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections

Also Published As

Publication number Publication date
WO2021207517A2 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
WO2021207517A3 (en) Modified hr2 peptide inhibitors of coronavirus fusion
MX2023003255A (en) Crispr-cas effector polypeptides and methods of use thereof.
EP4360647A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
WO2009025759A8 (en) Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
ATE546533T1 (en) RECOMBINANT EXPRESSION OF PROTEINS IN A DISULFIDE-BRIDGED, TWO-CHAIN FORM
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2013003045A3 (en) Procoagulant peptides and their derivatives and uses therefor
WO2006038131A3 (en) Inhibitors of infection
WO2021194826A3 (en) Recombinant sars-cov-2 spike protein and uses thereof
MX2022007858A (en) Crispr-cas effector polypeptides and methods of use thereof.
NO20063556L (en) HIV gp41 HR2-derived synthetic peptides and their use in treating human lack of virus immunity
MX2020006822A (en) Single-domain antibody-cytosine deaminase fusion proteins.
BRPI0720879A2 (en) microvesicle derived from tissue factor carrier (tf) carrier, composition and pharmaceutical composition comprising it, processes for its manufacture, modified tissue factor (tf) lipid protein, polynucleotide, vector, host cell and antibody.
WO2019148194A3 (en) Peptidyl inhibitors of calcineurin-nfat interaction
AU2016204400A1 (en) Method of inducing an immune response
WO2020168151A3 (en) Quantitative mapping of chromatin associated proteins
WO2018129200A3 (en) Pac1 receptor agonists (maxcaps) and uses thereof
MX2023002413A (en) Immunogenic coronavirus fusion proteins and related methods.
ZA202308985B (en) Constructs and methods for increased expression of polypeptides
WO2023039534A3 (en) Compositions comprising a cas12i polypeptide and uses thereof
WO2021252975A3 (en) Split intein-based selection for peptide binders
WO2010039223A3 (en) T-cell immunogens derived from anti-viral proteins and methods of using same
EP3771719A8 (en) A peptide binding to tau-protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21784912

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21784912

Country of ref document: EP

Kind code of ref document: A2